全文获取类型
收费全文 | 60620篇 |
免费 | 4798篇 |
国内免费 | 145篇 |
专业分类
耳鼻咽喉 | 473篇 |
儿科学 | 2391篇 |
妇产科学 | 1585篇 |
基础医学 | 8675篇 |
口腔科学 | 1067篇 |
临床医学 | 8316篇 |
内科学 | 11891篇 |
皮肤病学 | 1106篇 |
神经病学 | 6156篇 |
特种医学 | 1374篇 |
外科学 | 5445篇 |
综合类 | 550篇 |
一般理论 | 82篇 |
预防医学 | 7427篇 |
眼科学 | 836篇 |
药学 | 3590篇 |
2篇 | |
中国医学 | 70篇 |
肿瘤学 | 4527篇 |
出版年
2024年 | 86篇 |
2023年 | 644篇 |
2022年 | 861篇 |
2021年 | 1806篇 |
2020年 | 1288篇 |
2019年 | 1982篇 |
2018年 | 2108篇 |
2017年 | 1584篇 |
2016年 | 1757篇 |
2015年 | 1819篇 |
2014年 | 2324篇 |
2013年 | 3405篇 |
2012年 | 4822篇 |
2011年 | 4929篇 |
2010年 | 2643篇 |
2009年 | 2350篇 |
2008年 | 3839篇 |
2007年 | 3965篇 |
2006年 | 3914篇 |
2005年 | 3652篇 |
2004年 | 3436篇 |
2003年 | 3167篇 |
2002年 | 2877篇 |
2001年 | 441篇 |
2000年 | 323篇 |
1999年 | 396篇 |
1998年 | 623篇 |
1997年 | 493篇 |
1996年 | 418篇 |
1995年 | 404篇 |
1994年 | 308篇 |
1993年 | 316篇 |
1992年 | 219篇 |
1991年 | 187篇 |
1990年 | 173篇 |
1989年 | 133篇 |
1988年 | 140篇 |
1987年 | 108篇 |
1986年 | 108篇 |
1985年 | 106篇 |
1984年 | 119篇 |
1983年 | 120篇 |
1982年 | 147篇 |
1981年 | 152篇 |
1980年 | 118篇 |
1979年 | 73篇 |
1978年 | 79篇 |
1977年 | 81篇 |
1976年 | 62篇 |
1971年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Susan E. Hickman Alexia M. Torke Greg A. Sachs Rebecca L. Sudore Anne L. Myers Qing Tang Giorgos Bakoyannis Bernard J. Hammes 《Journal of pain and symptom management》2019,57(6):1143-1150.e5
ContextIt is especially important that patients are well informed when making high-stakes, preference-sensitive decisions like those on the Physician Orders for Life-Sustaining Treatment (POLST) form. However, there is currently no way to easily evaluate whether patients understand key concepts when making these important decisions.ObjectivesTo develop a POLST knowledge survey.MethodsExpert (n = 62) ratings of key POLST facts were used to select items for a POLST knowledge survey. The survey was administered to nursing facility residents (n = 97) and surrogate decision-makers (n = 112). A subset (n = 135) were re-administered the survey after a standardized advance care planning discussion to assess the scale's responsiveness to change.ResultsThe 19-item survey demonstrated adequate reliability (α = 0.72.). Residents' scores (x = 11.4, standard deviation 3.3) were significantly lower than surrogate scores (x = 14.7, standard deviation 2.5) (P < 0.001). Scores for both groups increased significantly after administration of a standardized advance care planning discussion (P < 0.001). Although being a surrogate, age, race, education, cognitive functioning, and health literacy were significantly associated with higher POLST Knowledge Survey scores in univariate analyses, only being a surrogate (P < 0.001) and being white (P = 0.028) remained significantly associated with higher scores in multivariate analyses.ConclusionThe 19-item POLST Knowledge Survey demonstrated adequate reliability and responsiveness to change. Findings suggest the survey could be used to identify knowledge deficits and provide targeted education to ensure adequate understanding of key clinical decisions when completing POLST. 相似文献
3.
4.
5.
6.
7.
P. Anne Scott 《Nursing philosophy》2019,20(3)
This paper revisits a 2003 publication in Nursing Philosophy: The need for accurate perception and informed judgement in determining the appropriate use of the nursing resource: hearing the patient's voice. The author suggests that the basic ideas and focus of this 16‐year‐old paper are still topical and relevant in considerations of nursing care. However, it is also suggested that greater attention to the importance of the nurse–patient relationship in considerations of resource allocation, and potential rationing of nursing care, would have strengthened the original paper. 相似文献
8.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
9.
10.